Tech Company Financing Transactions
Sequenta Funding Round
Sequenta, based in South San Francisco, secured investment capital from Celgene and private investors.
Transaction Overview
Company Name
Announced On
10/20/2014
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Celgene (Rajesh Chopra)
Proceeds Purpose
This financing, in addition to funding secured from several other strategic investors, will support incorporation of the ClonoSIGHT minimal residual disease (MRD) test into clinical trials of medicines in development for various hematological malignancies (blood cancers) and development of new clinical diagnostics based on Sequenta's revolutionary LymphoSIGHT platform.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
400 East Jamie Court 301
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Not Recorded
Overview
Sequenta is a venture funded biotech company dedicated to the discovery and development of clinical diagnostics based on a revolutionary new platform for understanding immune system status.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tom Willis
Chief Scientific Officer
Malek Faham
Browse more venture capital transactions:
Prev: 10/20/2014: Recurly venture capital transaction
Next: 10/20/2014: Viableware venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. All VC database entries reported here are derived from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs